SUBSCRIBE
SUBSCRIBE
News   Drug Development

Japan’s Eisai Inc. to Delay Parkinson’s Drug Submission

October 30, 2007 | 
1 min read

TOKYO, Oct 30 (Reuters) - Japanese drug maker Eisai Co Ltd (4523.T: Quote, Profile, Research) said on Tuesday it would delay submission of its U.S. and European applications for a drug candidate to treat Parkinson’s disease.

Clinical research Phase III Asia
MORE ON THIS TOPIC
Two human hands with a gesture of a handshake agreement and dollar banknotes with dollar signs on a colored background. Concept of business contract or agreement. Collage art
Cancer
BeiGene Gets Yet Another Label Expansion for PD-1 Drug Tevimbra
March 4, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Signage at Pfizer's world headquarters in New York City
Manufacturing
Pfizer Prepared to Reshore Manufacturing if Trump Makes Good on Tariff Threats
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
A white blood cell charging an ADC/
Antibody-drug conjugate (ADC)
AstraZeneca and Daiichi Sankyo’s Enhertu Enhances Stomach Cancer Case With Phase III Win
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac
Business consultant. Hands help a businessman is falling from a graph vector
Neuropsychiatric disorders
Biohaven Disappoints Again, This Time in Phase II/III Bipolar Mania Trial
March 4, 2025
 · 
2 min read
 · 
Tristan Manalac